All In Biotech

Drug Trial Radar · NCT00146757

A Study Evaluating the Safety and Pharmacokinetics of Aldurazyme® (Laronidase) in MPS I Patients Less Than 5 Years Old

A Phase II Open-Label Clinical Trial of Recombinant Human Alpha-L-iduronidase (Aldurazyme®) to Evaluate the Safety and Pharmacokinetics in Mucopolysaccharidosis I (MPS I) Patients Less Than 5 Years Old

Last checked: Nov 20, 2026Latest source record: Apr 3, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

20

Actual

Start

Oct 2002

Primary completion

May 2005

Study completion May 2005

Sponsor

Lead sponsor
Genzyme, a Sanofi CompanySanofi (SNY)
Sponsor type
Industry
Collaborators
BioMarin/Genzyme LLC
First posted
Sep 7, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, up to 5 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main objectives of this study are to evaluate the safety and pharmacokinetics (PK) of enzyme replacement therapy with recombinant human alpha-L-iduronidase \[Aldurazyme® (laronidase)\] in mucopolysaccharidosis I (MPS I) patients less than 5 years old. Efficacy measurements will also be evaluated in this study.

Conditions

  • Mucopolysaccharidosis I
  • Hurler Syndrome
  • Hurler-Scheie Syndrome
  • Scheie Syndrome

Interventions

  • Aldurazyme (Recombinant Human Alpha-L-Iduronidase)Biological

    100 U/kg every week

  • Aldurazyme (Recombinant Human Alpha-L-Iduronidase)Biological

    200 U/kg every week (Week 26 onwards)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety EvaluationTime frame: 52 weeks
  2. Pharmacokinetics - Area Under the (Plasma Concentration-time) Curve (AUC∞)Time frame: 52 weeks
  3. Pharmacokinetics - Elimination Half Life (t1/2)Time frame: 52 weeks
  4. Pharmacokinetics - Total Plasma Clearance (CL)Time frame: 52 weeks
  5. Pharmacokinetics - Volume of Distribution (Vz)Time frame: 52 weeks

Locations

4 sites in 4 countries. Site status is shown where the registry gives one.

  • Hôpital E. Herriot

    Lyon, France

  • Johannes Gutenberg Universität

    Kinderklinik, Mainz, Germany

  • Sophia Children's Hospital

    Rotterdam, Netherlands

  • Willink Biochemical Genetics Unit Royal Hospital for Children

    Manchester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.